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Abstract: The interactions between genetic variants in estrogen receptor (ER) have been identiﬁ  ed to be associated with 
an increased risk of breast cancer. Available evidence indicates that genetic variance within a population plays a crucial role 
in the occurrence of breast cancer. Thus, the comparison and identiﬁ  cation of ER-related gene expression proﬁ  les in breast 
cancer of different ethnic origins could be useful for the development of genetic variant cancer therapy. In this study, we 
performed microarray experiment to measure the gene expression proﬁ  les of 59 Taiwanese breast cancer patients; and 
through comparative bioinformatics analysis against published U.K. datasets, we revealed estrogen-receptor (ER) related 
gene expression between Taiwanese and British patients. In addition, SNP databases and statistical analysis were used to 
elucidate the SNPs associated with ER status. Our microarray results indicate that the expression pattern of the 65 genes in 
ER+ patients was dissimilar from that of the ER- patients. Seventeen mutually exclusive genes in ER-related breast cancer 
of the two populations with more than one statistically signiﬁ  cant SNP in genotype and allele frequency were identiﬁ  ed. 
These 17 genes and their related SNPs may be important in population-speciﬁ  c ER regulation of breast cancer. This study 
provides a global and feasible approach to study population-unique SNPs in breast cancer of different ethnic origins.
Keywords: estrogen receptor, breast cancer, microarray, gene expression proﬁ  le
Introduction
Breast cancer is one of the most common cancers for women in the world as it ranks number one among 
other cancers in developed countries, and ranks fourth in Taiwan. Current research suggests that inter-
actions between genetic variants and a wide range of environmental factors may contribute to the 
development of breast cancer. Available evidence indicates that genetic variance within the population 
plays a role in the probability of breast cancer development, with a low incidence in certain groups of 
Asian women to the highest in Caucasian women (Hsiao et al. 2004).
With microarray technique, large amounts of gene expression data can be obtained in a short period 
of time. Gene expression proﬁ  ling is a powerful tool for identifying gene activity patterns, which enables 
the distinction among various subtypes of breast cancer (including luminal subtypes A and B, and ERBB2 
between basal and normal) (Sorlie et al. 2001). According to the data from both clinical and animal studies, 
estrogen is crucial to the development and progression of breast cancer. Estrogen mediates its effects 
through the estrogen receptor (ER), which serves as the basis for many therapeutic interventions (Deroo 
and Korach, 2006). More than two-thirds of breast cancers show estrogen receptor expression at the time 
of diagnosis, and immunohistochemical detection of estrogen receptor expression is routinely used in 
making decisions on hormonal therapy for breast cancer (Holst et al. 2007). Gene variants in steroid 36
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hormone related genes, ESR1, ESR2, PGR, and 
HSD17B1 have been identiﬁ  ed to be associated with 
either an increased or decreased risk of breast can-
cer (Feigelson et al. 2006; Gold et al. 2004); how-
ever, the exact associations remain unclear. 
Furthermore, ER-α allelic variants have been 
reported to be associated with the risk for breast 
cancer (Gold et al. 2004) in Caucasians and in Tai-
wanese (Hsiao et al. 2004). Certain single nucleotide 
polymorphisms (SNPs) may inﬂ  uence the regulation 
of ERs and coregulators on tumor development and 
progression. In this study, we developed an approach 
to ﬁ  nd out population-unique SNPs in breast cancer 
of different ethnic origins by comparing the gene 
expression proﬁ  les of two different populations and 
related SNP data.
Materials and Methods
Tumor tissue samples 
and examination of ER
Surgical specimens of breast cancer tumor tissue 
were freshly collected and snap frozen from patients 
who underwent surgery at National Taiwan Univer-
sity Hospital (NTUH) between 2002 and 2005. 
Cancer samples containing relatively pure tumor, 
as deﬁ  ned by greater than 50% tumor cells per high-
power ﬁ  eld examined in a section adjacent to the 
tissue used, were included in this study. All the 
parafﬁ  n sections of breast cancer specimens (3–5 m 
in thickness ) on slides were processed in Ventana’s 
automated staining system (BenchMark â LT) 
(Ventana Medical System Inc., Tucson , AZ, U.S.A.) 
for the immunohistochemical stain (IHC). Firstly 
the slides were probed with CONFIRMTM anti-
Estrogen Receptor (SP1) rabbit monoclonal primary 
antibody (Catalog # 790-4325, Ventana Medical 
System Inc.). Secondly, to localize and visualize ER 
protein within the specimen, iVIEW TM DAB 
Detection kit (Catalog # 760-091, Ventana Medical 
System Inc.) was applied. The negative control 
slides for tumor specimens were solely stained using 
iVIEWTM DAB Detection kit (Catalog # 760-091, 
Ventana Medical System Inc.).
RNA extraction and oligo microarray
Total RNA was extracted by Trizol
® Reagent 
(Invitrogen, U.S.A.), followed by RNeasy Mini 
Kit (Qiagen, Germany). Puriﬁ  ed RNA is quantiﬁ  ed 
at OD260nm by a ND-1000 spectrophotometer 
(Nanodrop Technology, U.S.A.) and quality-
controlled by Bioanalyzer 2100 (Agilent Technol-
ogy, U.S.A.). A human reference RNA pooled from 
10 cell lines (Stratagene, U.S.A.) was used to serve 
as reference in microarray comparison. 0.5 g of 
total RNA was ampliﬁ  ed by a Low RNA Input 
Fluor Linear Amp kit (Agilent Technologies) and 
labeled with Cy3 or Cy5 (CyDye, PerkinElmer, 
U.S.A.) during the in vitro transcription process. 
Tumor RNA was labeled with Cy5 and RNA from 
Universal Human Reference RNA was labeled with 
Cy3. 2 g of Cy-labeled cRNA was fragmented to 
an average size of about 50–100 nucleotides by 
incubating with fragmentation buffer at 60 °C for 
30 minutes. Correspondingly fragmented labeled 
cRNA is then pooled and hybridized to Human 1A 
(version 2) oligo microarray (Agilent Technolo-
gies) at 60 °C for 17 h. After washing and drying 
with nitrogen gun blowing, microarrays are 
scanned with an Agilent microarray scanner 
(Agilent Technologies, U.S.A.) at 535 nm for Cy3 
and 625 nm for Cy5. Scanned images are analyzed 
by Feature Extraction software 6.0 (Agilent Tech-
nologies, U.S.A.), and each feature is quantiﬁ  ed 
by Feature Extraction to output the signal and 
background intensity; the data are substantially 
normalized by rank-consistency-ﬁ  ltering LOWESS 
method.
Microarray data analysis
In this study, we used microarray technique to pro-
ﬁ  le the gene expression of 59 breast cancer patients 
in Taiwan with primary invasive breast carcinoma. 
For the comparison of the gene expression proﬁ  les 
between Taiwanese and U.K. patients, we used U.K. 
breast cancer data from the National Cancer Institute 
(NCI) which were obtained from the online supple-
mentary materials of Sotiriou et al. (Sotiriou et al. 
2003). Detailed information and clinical character-
istics for breast cancer patients in the U.K. and 
Taiwan are shown in Table 1. The gene expression 
datasets from our microarray results and that of NCI 
were grouped into ER+ and ER− respectively 
according to their clinical prognosis variables shown 
in Figure 1. To identify differentially expressed 
genes between the two groups and to increase the 
accuracy of signiﬁ  cant gene selection, combination 
of Signiﬁ  cance Analysis of Microarrays (SAM) 
(Tusher et al. 2001) and Optimal Discovery Proce-
dure (ODP) (Storey, 2005) were jointly used for the 
selection of differentially expressed genes.37
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Table 1. Summary of microarray information and clinical characteristics of NTUH and NCI datase.
Identiﬁ  ers  NTUH  NCI
Institute National  Taiwan  John  Radcliffe
 University  Hospital  Hospital
Populations Taiwanese  Caucasian
Microarray platform  Agilent human 1Av2  cDNA (NCI)
Sample size, No.  59  99
ER status, No. (%)   
  Positive  44 (73.3)  65 (65.6)
  Negative  15 (25.0)  34 (34.3)
 Unknown  0  0
Lymph node status, No. (%)   
  Positive  34 (57.6)  53 (53.5)
  Negative  21 (35.6)  46 (46.5)
 Unknown  4  (6.8)  0
Histological grade, No. (%)     
  1  14 (23.7)  16 (16.2)
  2  31 (52.5)  38 (38.4)
  3  12 (20.3)  45 (45.4)
 Unknown  2  (3.3)  0
Tumor size, No. (%)   
  2 cm  13 (22.0)  36 (36.4)
  2cm  20 (33.9)  63 (63.6)
 Unknown  26  (44.1)  0
  Reference  this study  Sotiriou et al. [9]
*ER: estrogen receptor.
Figure 1. Flowchart for the gene expression-based comparative analysis. Microarray gene expression data of the NCI dataset (breast 
cancer patients in the U.K.) and the NTUH dataset (breast cancer patients in Taiwan) were separated into ER+ and ER− groups respectively for 
further identiﬁ  cation of signiﬁ  cantly differentially expressed genes through statistical algorithms, Signiﬁ  cant Analysis of Microarrays (SAM) and 
Optimal Discovery Procedure (ODP). 88 genes in the NCI dataset and 65 genes in the NTUH dataset were selected. After mapping these selected 
genes against the common gene pool between both datasets, 67 mutually exclusive genes were chosen for the SNP analysis. After examining 
the genotype and allele frequency of these 67 genes using chi-square test (p-value 0.001), 83 SNPs in the 17 genes were identiﬁ  ed.38
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Hierarchical clustering
Hierarchical clustering was processed by Multiple-
Experiment Viewer (MeV) 4.0, an open source 
software which is part of the TM4 Software Suite 
(Saeed et al. 2003) created by The Institute for 
Genomic Research (TIGR, Rockville, MD). 
Euclidean distance and average linkage were used 
to measure the distance of gene expression.
SNP search and statistical analysis
SNP information was retrieved from the Perlegen 
Genotype Browser (http://genome.perlegen.com/
browser/index_v2.html) and dbSNP (http://www.
ncbi.nlm.nih.gov/projects/SNP/). Perlegen Geno-
type Browser and dbSNP contain SNP information 
of three ethnic populations, African American, 
European American, and Chinese. For the purpose 
of this study, we focused on the SNPs of European 
American and Chinese to represent the United 
Kingdom (U.K.) and Taiwanese populations 
respectively for further statistical analysis. SNPs 
in the 67 candidate genes were initially searched 
and browsed through the Perlegen Genotype 
Browser. The SNPs with differences in allele fre-
quencies between European American and Chinese 
were manually screened for further analysis. In 
order to collect detailed information on the rest of 
the SNPs, we referred to dbSNP and retrieved the 
genotype and allele frequencies of the two popula-
tions. Through Pearson’s chi-square tests, the SNPs 
of our candidate genes that were signiﬁ  cantly dif-
ferentiated in both genotype and allele frequencies 
between European American and Chinese were 
identiﬁ  ed. We utilized R software for the statistical 
analysis of SNPs.
Results
Differentially expressed genes 
in ER+/ER− breast cancer subgroups
First, we used immunohistochemical stain to exam-
ine ER+/ER− breast cancer tissue subgroups 
(Fig. 2). The microarray data were grouped into 
ER+ and ER− groups based on the ER status of 
breast cancer patients. In order to select the dif-
ferentially expressed genes, we combined two 
algorithms, Signiﬁ  cance Analysis of Microarray 
(SAM) (Tusher et al. 2001) and Optimal Discovery 
Procedure (ODP) (Storey, 2005). Using two-class 
Figure 2. Immunohistochemical stain of ER in Taiwanese breast cancer tissues. (A) and (C) ER− 200X and 40X; (B) and (D) ER+ 200X 
and 40X. The microarray experiments were performed by using these examined tissues.
B A
C D39
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unpaired SAM supervised analysis, and setting the 
imputation engine at 10 K-nearest neighbors, we 
found 78 differentially expressed genes from our 
data, in which 31 of them were up-regulated and 
47 were down-regulated. After applying ODP 
algorithm and imputing missing data, 737 genes 
with q-value under cut-off at 0.01 were then 
selected. 65 genes were simultaneously picked up 
by both SAM and ODP analysis, and were regarded 
as the most signiﬁ  cant genes. The ﬂ  owchart for 
candidate gene selection is shown in Figure 1. The 
log2 transformed data of the genes differentially 
expressed between ER+ and ER− groups are shown 
in the hierarchical clustering diagram (Fig. 3a). 
The expression pattern of the 65 genes in ER+ 
patients (Fig. 3a, left) was dissimilar from that of 
the ER− patients (Fig. 3a, right). Similarly, in the 
NCI dataset, 107 genes were selected using SAM 
algorithm (genes with missing gene symbol were 
excluded); 56 of them were up-regulated and 51 
were down-regulated. 900 genes were considered 
as signiﬁ  cant genes by the ODP algorithm, and 
these genes included the 88 genes selected by 
SAM, which were regarded as the most signiﬁ  cant 
genes in the NCI dataset. Hierarchical clustering 
diagram displays the gene expression pattern of 
these 88 genes in Figure 3b.
Comparison of differentially 
expressed genes in our and NCI data
The microarrays used in our and NCI datasets have 
3197 gene probes in common, and were designated 
as our candidate gene pool for analysis. Shown in 
Figure 4, with regard to our candidate gene pool, 
in the NTUH dataset, 9 of 65 signiﬁ  cant genes fell 
in this block region (3197 common genes for both 
NTUH and NCI datasets); while 68 of 88 genes 
fell in the same block in the NCI dataset. Five genes 
found in the overlapping region were the common 
Figure 3. Hierarchical clustering diagrams of (a) NTUH dataset and (b) NCI dataset. Genes with similar expression pattern (vertical) 
and breast cancer samples with similar ER statuses (horizontal) were hierarchically clustered together. For the NTUH dataset, the majority 
of ER+ samples are on the left region (from 1595 M to 1257 M, except for 1431 M and 1587 M) while the majority of ER− are on the right; 
for the NCI dataset, few ER− samples fell under the ER+ group (X 21643 and X21618), as most ER− samples were clustered in the middle 
or on the right The clustering results conﬁ  rmed our selection of differentially expressed genes in ER+/ER− groups, representing distinct gene 
expressions between NTUH and NCI datasets.
a b40
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genes among the signiﬁ  cant genes from the two 
datasets, implying these genes were differentially 
expressed in both Taiwanese and U.K. patients. 
They are basic transcription factor 3 (BTF3), 
cyclin-dependent kinase inhibitor 2A (CDKN2A), 
estrogen receptor 1 (ESR1), GATA binding protein 
3 (GATA3), and trefoil factor 3 (TFF3). All of these 
ﬁ  ve genes have already been reported to be associ-
ated with ER status in human breast cancers. There 
were 67 differentially expressed candidate genes 
appearing exclusively in either the Taiwanese or 
the U.K. patients, as depicted by the Venn diagram 
(Fig. 4). These 67 mutually exclusive genes drew 
our attention since they might reﬂ  ect the differ-
ences between the two populations, and may 
potentially inﬂ  uence the ER status in each popula-
tion. Further details about these genes are shown 
in Table 2.
Association analysis of SNPs 
in different ethnic origins
Since the SNP information of many human genes 
is available, we searched for possible SNP varia-
tions of these 67 genes between the representative 
populations of Taiwanese and U.K. patients in 
public databases. These results, namely the popu-
lation-unique SNPs in the mutually exclusive 
genes, may imply the associations of these SNPs 
with ER status in breast cancer of different ethnic 
origins. Perlegen Genotype Browser and dbSNP, 
two public SNP databases, were useful for our 
association analysis of SNPs. Perlegen Genotype 
Browser includes SNP information on three ethnic 
populations, African American, European Ameri-
can, and Chinese. We chose the SNPs of European 
American and Chinese to represent the U.K. and 
Taiwanese populations respectively for further 
statistical analysis. Using a cutoff p-value of 0.001, 
Pearson’s chi-square test identiﬁ  ed 17 candidate 
genes which could be potential focuses in breast 
cancer development, including damage-speciﬁ  c 
DNA binding protein 2 (DDB2), ATP-binding cas-
sette, sub-family D (ALD) and member 3 (ABCD3), 
ATPase, Na+/K+ transporting, beta 3 polypeptide 
(ATP1B3), sphingosine kinase type 1 interacting 
protein (SKIP), developmentally regulated GTP 
binding protein 1 (DRG1), interleukin-1 receptor-
associated kinase 1 (IRAK1), keratin 7 (KRT7), 
dipeptidyl-peptidase 6 (DPP6), E2F transcription 
factor 3 (E2F3), fucosyltransferase 8 (FUT8), 
hydroxysteroid (17-beta) dehydrogenase 
4 (HSD17B4), lipin 1 (LPIN1), myosin VI 
(MYO6), nuclear factor I/B (NFIB), protein tyro-
sine phosphatase, non-receptor type substrate 1 
(PTPNS1), syndecan 4 (SDC4), and seven in 
absentia homolog 2 (SIAH2). These genes had 
more than one statistically significant SNP 
(p-value  0.001) in genotype and allele frequency 
between our and NCI datasets. A total of 83 SNPs 
among the 17 genes were identiﬁ  ed. Genes with 
the most statistically signiﬁ  cant SNPs between 
European American and Chinese are as follows: 
DPP6 (19 SNPs), followed by HSD17B4 (13 
SNPs), ABCD3 (10 SNPs), and FUT8 (9 SNPs). 
The remaining genes have fewer than ﬁ  ve signiﬁ  -
cant SNPs. In Table 3, the differential genes with 
their possible related SNPs are presented.
Functional study of identiﬁ  ed genes
In order to understand the functions of the 17 
identiﬁ  ed genes and their possible relationships 
with ER expression, we used DAVID database 
(Database for Annotation, Visualization and Inte-
grated Discovery) (Dennis et al. 2003) to perform 
this analysis. These genes were functionally 
classiﬁ  ed into the following six categories: alterna-
tive splicing (DPP6, PTPNS1, NFIB, MYO6, 
SKIP, IRAK1, DDB2, and FUT8), signal-anchor 
Figure 4. The Venn diagram of signiﬁ  cant genes in our and NCI 
datasets. In order to compare the difference of differentially 
expressed genes selected in NTUH and NCI datasets, we only focus 
on the gene probes common in both datasets. After ﬁ  ltering out the 
genes only present in either NTUH or NCI datasets, a total number 
of 3197 genes were left, and were considered as our common can-
didate gene pool for further identiﬁ  cation. In the NCI dataset, 68 of 
the 88 differentially expressed genes (refer to Fig. 1) were in the pool; 
while NTUH dataset has 9 genes left in the pool. The 67 mutually 
exclusive genes were selected for further SNP analysis.41
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(DPP6, ATP1B3, FUT8), sh3-binding 
(PTPNS1, FUT8), disease mutation (HSD17B4, 
MYO6, ABCD3, DDB2), peroxisome (HSD17B4, 
ABCD3), and nucleotide-binding (MYO6, 
ABCD3, IRAK1, DRG1). As expected, all of the 
observed functions are either directly or indirectly 
involved in the regulation of estrogen receptors, in 
particular the genes closely associated with alterna-
tive splicing, sh3-binding, disease mutation, and 
peroxisome (Bonoﬁ  glio et al. 2005; Pfeffer et al. 
1996; Troester et al. 2006; Zhou et al. 2006).
Discussion
According to the result of SNP analysis, 83 SNPs 
from the 17 differentially expressed genes in either 
the Taiwanese or U.K. ER+/ER− breast cancers 
were identiﬁ  ed (Table 3). The ﬁ  ndings indicate 
these 17 genes and their related SNPs may be 
important in the ER regulation in breast cancer of 
different populations. Since many reports have 
showed the association of genetic variations of 
estrogen receptor and breast cancer (Iwase H, 1996; 
Kang et al. 2002; Roodi et al. 1995), it is worthy 
to presume that the 83 identiﬁ  ed SNPs in ER-
related genes may very well have either direct or 
indirect inﬂ  uence on the ER status in breast cancer 
of different ethnic populations. Here we used SNPs 
to represent the polymorphisms between Taiwan 
and U.K. populations since they are good indicators 
for measuring the genetic differences between two 
different ethnic origins. Moreover, among the 17 
signiﬁ  cant genes mentioned above, only DDB2 
was from our data, while the rest of the 16 genes 
were from the NCI data. DDB2 is known for its 
function in DNA binding while it also acts as a 
tumor suppressor. A recent study provides further 
evidence that rs830083 polymorphisms in DDB2 
may contribute to the etiology of lung cancer in 
Chinese population (Hu et al. 2006). This corre-
sponds to our study in that the SNPs we identiﬁ  ed 
in DDB2 may play a role in speciﬁ  c regulation of 
estrogen receptor in Chinese breast cancer 
patients.
Except for DDB2, the expressions of the other 
16 genes, ABCD3, ATP1B3, SKIP, DRG1, IRAK1, 
KRT7, DPP6, E2F3, FUT8, HSD17B4, LPIN1, 
MYO6, NFIB, PTPNS1, SDC4, and SIAH2, are 
different in ER-positive and ER-negative U.K. 
patients. ATP1B3 is derived from the primary dif-
ferentiation event during mammalian development 
(Adjaye et al. 2005). IRAK1 has been proposed 
that one SNP within it, when combined with high-
risk genotype at TLR6-1-10, conferred a signiﬁ  cant 
increase in the risk for prostate cancer, suggesting 
synergistic effects between sequence variants in 
IRAK1 and the TLR 6-1-10 gene cluster (Sun et al. 
2006). LPIN1 is reported to be a candidate gene 
for human lipodystrophy syndromes as common 
SNPs in LPIN1 of lipodystrophy patients have been 
identified (Cao and Hegele, 2002). Limited 
research has been done on the genetic variants in 
these genes, but the correlations of these ER-
related genes and tumorigenesis are likely to cor-
respond to an increase in susceptibility for breast 
cancer. Cytokeratin 7 (encoded by KRT7/CK7) is 
found in the majority of type 1 papillary renal cell 
carcinomas and chromophobe renal cell carcino-
mas, and its expression proﬁ  le alteration is par-
ticularly associated with tumorigenesis of primary 
adenocarcinoma of the small intestine (Chen and 
Wang, 2004; Mazal et al. 2005). SDC4 is a cell-
adhesion molecule related to the enhanced adhe-
sion of cancer cells to ﬁ  bronectin (Koike et al. 
2004), and functions as a receptor in intracellular 
signaling. A study has showed SKIP to be a protein 
likely to participate in the regulation of SPHK1 
activity modulation, but much about its functions 
remain unknown. The association between estro-
gen and SIAH2 has been illustrated by a mecha-
nism in which the estrogen-ER complex markedly 
reduces the level of N-CoR through a process 
related to the up-regulation of SIAH2 and the 
subsequent targeting of N-CoR for proteasomal 
degradation (Frasor et al. 2005).
The genes, BTG2, ISL1, MCP (also known as 
CD46), SIAH2, and XBP1, in the list of mutually 
exclusive subset shown in Table 2 were previously 
known to be associated with ER status (Frasor et al. 
2005; Gay et al. 2000; Kawakubo et al. 2006; 
Lacroix and Leclercq, 2004; Rushmere et al. 2004). 
These ﬁ  ve ER-regulated genes were only observed 
to be differentially expressed in the NCI dataset, 
but not in our dataset. Intriguingly, the majority of 
published reports used breast cancer cell lines 
extracted from Caucasian patients in their studies. 
One possible explanation for this phenomenon is 
that the association of these ﬁ  ve genes and estrogen 
is solely limited to Caucasian breast cancers 
patients.
In addition, ﬁ  ve genes, BTF3, CDKN2A, ESR1, 
GATA3, and TFF3, fell in the overlapping subset 
as shown in Figure 4, meaning they were identiﬁ  ed 
to be differentially expressed in both our and the 46
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Table 3. List of identiﬁ  ed genes and SNPs.
ER+/ER− Gene 
symbol
SNP ID Dominant 
genotype*
p-value Dominant p-value odd ratios
↑ DDB2 rs3781619
b GG/AA 1.09E-05 G/A 6.21E-08 0.05 (7.9E-3∼0.17)
rs2306353
c TT/AA 1.09E-05 T/A 6.21E-08 0.05 (7.9E-3∼0.17)
rs2050648
b AG/GG 4.45E-04 A/G 5.02E-05 7.36 (2.59–23.50)
rs10493872
f GT/TT 6.14E-06 T/T 1.80E-06 Inf (7.52-Inf)
rs4847303
f AG/GG 4.45E-04 A/G 5.02E-05 7.36 (2.59–23.50)
rs12143221
b AG/AA 4.45E-04 G/A 5.02E-05 0.14 (0.04–0.39)
↑ ABCD3 rs2147794
b AG/AA 4.45E-04 G/A 5.29E-05 0.13 (0.04–0.39)
rs17410399
b AT/AA 4.45E-04 T/A 5.29E-05 0.13 (0.04–0.39)
rs1158254
a AC/CC 4.45E-04 A/C 5.02E-05 7.36 (2.59–23.50)
rs16946
b AG/GG 4.45E-04 A/G 5.02E-05 7.36 (2.59–23.50)
rs4148050
b AG/GG 4.45E-04 A/G 5.02E-05 7.36 (2.59–23.50)
rs2296382
e CT/CC 4.45E-04 T/C 5.02E-05 0.14 (0.04–0.39)
↓ ATP1B3 rs2068229
b AA/GG 7.56E-04 A/G 3.68E-05 6.77 (2.56–19.32)
↑ SKIP rs1879488
a CC/AC 5.57E-07 C/C 7.09E-05 0 (0–0.12)
rs2273252
d CC/CG 6.14E-06 C/C 4.00E-06 Inf (6.89-Inf)
↓ DRG1 rs6518745
e TT/CC 1.98E-07 T/C 3.70E-11 0.01 (2.3E-4∼0.07)
rs5994397
d CC/GG 1.91E-07 C/G 1.16E-11 107.32 (15.37–4591.03)
↓ IRAK1 rs1059703
b AA/GG 1.37E-04 A/G 3.34E-07 10.95 (3.99–32.85)
rs7061789
b AA/GG 9.85E-06 A/G 9.10E-09 16.88 (5.68–57.34)
rs936331
e CC/TT 1.69E-04 C/T 1.38E-05 0.13 (0.04–0.35)
↓ KRT7 rs1317649
e CC/TT 1.69E-04 C/T 1.38E-05 0.13 (0.04–0.35)
rs1870220
b,b GG/AA 1.69E-04 G/A 1.38E-05 0.13 (0.04–0.35)
rs878742
e CC/TC 7.00E-05 C/C 9.45E-05 0.11 (0.02–0.37)
rs4960626
b AA/AG,GG 1.00E-04 A/G 2.37E-06 14.79 (4.12–68.87)
rs4960625
b AA/AG 3.98E-05 A/G 1.44E-05 11.78 (3.37–53.66)
rs1568900
f GG/GT 2.13E-05 G/T 2.27E-06 11.69 (3.74–44.64)
rs877471
e CC/CT 1.70E-05 C/C,T 5.62E-06 14.57 (3.85–83.17)
rs1016103
d CC/CG 1.35E-05 C/G 1.57E-06 13.71 (4.07–60.83)
rs877472
e TT/CT 1.70E-05 T/C,T 5.62E-06 0.07 (0.01–0.26)
rs940848
b AA/AG 2.13E-05 A/G 2.27E-06 11.69 (3.74–44.64)
rs3800573
e TT/CT 2.23E-05 T/C 5.45E-06 0.09 (0.02–0.29)
↑ DPP6 rs3800574
c AA/AT 3.44E-05 A/T 5.80E-06 10.86 (3.45–41.68)
rs868880
b AA/AG 3.34E-05 A/G 2.27E-06 0.09 (0.02–0.27)
rs3778735
b GG/AG 8.97E-06 G/A 1.18E-06 0.07 (0.02–0.24)
rs3778739
b AA/AG 5.27E-05 A/G 7.66E-06 10.60 (3.37–40.71)
rs3778740
a CC/AC 5.49E-05 C/A 6.51E-06 0.08 (0.02–0.27)
rs2293356
e CC/TC 3.92E-04 C/T 1.93E-05 0.10 (0.03–0.32)
rs2293355
d CC/GC 4.92E-04 C/G 9.70E-06 0.10 (0.03–0.31)
rs2293354
b GG/AG 4.92E-04 G/A 9.70E-06 0.10 (0.03–0.31)
rs17515800
b GG/GG 3.36E-04 G/G 1.88E-05 Inf (5.73-Inf)
rs1110077
f TT/GT 6.68E-05 T/G 7.41E-06 0.10 (0.03–0.31)
rs9348428
e CC/CT 1.30E-05 C/T 3.96E-06 9.49 (3.33–30.65)
↓ E2F3 rs9348429
e TT/CC 6.68E-05 T/C 7.41E-06 0.10 (0.03–0.31)
rs16883824
e CC/CT 8.35E-05 C/T 2.23E-05 8.00 (2.82–25.63)
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rs17826580
a AA/AC 5.47E-04 A/A 2.81E-04 7.76 (2.50–29.34)
rs8018909
d GG/CG 5.47E-04 G/G 2.81E-04 0.13 (0.03–0.40)
rs17246259
b GG/AG 4.01E-04 G/A 6.31E-05 0.12 (0.03–0.37)
rs17826736
e TT/CT 4.01E-04 T/C,T 6.31E-05 0.12 (0.03–0.37)
↑ FUT8 rs2268957
e CC/CT 5.47E-04 C/C 2.81E-04 7.76 (2.50–29.34)
rs17826820
b GG/AG 5.47E-04 G/G 2.81E-04 0.13 (0.03–0.40)
rs1998035
b AA/AG 5.47E-04 A/A 2.81E-04 7.76 (2.50–29.34)
rs2300871
a AA/AC 5.47E-04 A/A 2.81E-04 7.76 (2.50–29.34)
rs2268960
b AA/AG 4.01E-04 A/A,G 6.31E-05 8.40 (2.69–31.91)
rs26181
e CT/TT 1.56E-05 T/T 7.52E-06 18.89 (4.12–178.26)
rs32651
b AG/AA 4.32E-06 A,G/A 1.41E-06 0.04 (4.8E-3∼0.21)
rs463513
b AG/GG 4.95E-05 G/G 1.68E-05 0.06 (6.0E-3∼0.26)
rs2459726
c AT/TT 1.91E-04 T/T 1.30E-04 10.46 (2.74–59.95)
rs2678070
b AG/GG 8.22E-05 G/G 7.81E-05 14.68 (3.17–139.58)
↑ HSD17B4 rs382719
e CT/CC 1.60E-05 C/C 1.68E-05 17.39 (3.78–164.30)
rs2636968
b AG/AA 1.60E-05 A/A 1.68E-05 0.06 (6.0E-3∼0.26)
rs26184
e CT/CC 1.60E-05 C/C 1.68E-05 0.06 (6.0E-3∼0.26)
rs2636961
e CT/TT 6.34E-05 C/T 6.15E-05 18.64 (4.93–106.85)
rs2678074
f GT/TT 6.34E-05 G/T 6.15E-05 18.64 (4.93–106.85)
rs2636962
a AC/CC 6.34E-05 A/C 6.15E-05 18.64 (4.93–106.85)
↓ LPIN1 rs4129757
b GG/AA 7.97E-05 G/A 2.35E-06 10.38 (3.58–33.54)
rs2748956
d CC/CG 5.47E-04 C/C 2.81E-04 7.12 (2.27–27.08)
rs1280050
b AG/GG 5.12E-05 G/G 3.66E-05 15.99 (3.47–151.33)
↑ MYO6 rs1280054
b AG/GG 5.12E-05 G/G 3.66E-05 15.99 (3.47–151.33)
rs910679
e CT/CC 5.12E-05 C/C 3.66E-05 0.06 (6.0E-3∼0.26)
rs1280053
b AG/AA 5.12E-05 A/A 3.66E-05 0.06 (6.0E-3∼0.26)
rs12236761
c TT/AT 5.57E-07 T/T 1.44E-07 0 (0–0.10)
↓ NFIB rs10961439
f TT/GT 1.68E-07 T/G 2.28E-08 0.06 (0.02–0.19)
rs12684749
b AA/AG 3.59E-08 A/A,G 2.46E-04 Inf (4.40-Inf)
rs10810120
e TT/CT 2.00E-07 T/C 6.55E-05 0.07 (0.02–0.20)
rs2267905
a AA/AC 3.70E-08 A/C 5.05E-09 36.71 (7.99–348.43)
↓ PTPNS1 rs2267906
e TT/CT 1.05E-06 T/C 9.57E-08 0.04 (3.7E-3∼0.16)
rs3197744
f TT/GG 5.17E-06 T/G 9.73E-10 0.03 (5.5E-3∼0.12)
↑ SDC4 rs6073718
b AG/AA 3.46E-05 A/A 1.94E-05 0.03 (7.7E-4∼0.23)
rs2267868
e CT/TT 3.46E-05 T/T 1.94E-05 29.89 (4.31–1297.07)
rs6789306
b AA/AG 5.55E-07 A/G 8.85E-07 43.10 (6.17–1873.77)
↑ SIAH2 rs7615292
b GG/AG 3.83E-06 G/G 9.69E-06 0.03 (6.9E-4∼0.21)
rs16862837
f GG/GT 4.45E-06 G/G 3.30E-06 20.52 (4.48–193.32)
rs1879421
b GG/AG 1.62E-06 G/G 5.33E-06 0 (0–0.14)
aGenotype frequency: AA, AC, CC. Allele frequency: A, C.
bGenotype frequency: AA, AG, GG. Allele frequency: A, G.
cGenotype frequency: AA, AT, TT. Allele frequency: A, T.
dGenotype frequency: CC, CG, GG. Allele frequency: C, G.
eGenotype frequency: CC, CT, TT. Allele frequency: C, T.
fGenotype frequency: GG, GT, TT. Allele frequency: G, T.
Note: Dominant genotype and allele represent the groups with the highest genotype and allele frequency. The left parts of the genotype 
and allele represent Caucasian, whereas the right parts represent Chinese.
↑, higher expression in ER+ samples; ↓ lower expression in ER- samples.48
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NCI datasets. All of these genes have been 
identiﬁ  ed and studied to play roles in ER regulation 
(Doane et al. 2006; Green et al. 2007; Milde-
Langosch et al. 2001; Oh et al. 2006). According 
to a study, speciﬁ  c interaction between BTF3 and 
ERalpha has been veriﬁ  ed in vivo and in vitro; 
moreover, BTF3 may inﬂ  uence the mechanism by 
which the AF-1 (transcriptional activation func-
tion) of ERalpha simulates gene expression 
(Green et al. 2007). GATA3, TFF3, and ESR1 are 
three estrogen-regulated genes known for their 
over-expression in luminal subtype A, which is 
primarily composed of ER+ (Chen and Wang, 
2004; Doane et al. 2006). Meanwhile, GATA3 is 
also a transcription factor serving as a curial com-
ponent in the tumorigenesis of ER+ breast cancer, 
and is involved in growth control and maintenance 
of the differentiated state in epithelial cells (Usary 
et al. 2004).
The SNPs identiﬁ  ed in our selected genes may 
be involved in determining whether ER expression 
causes disparities between Chinese and Caucasian 
breast cancer patients. Our work can provide pos-
sible SNPs associated with ER status in breast 
cancer of different ethnic origins and a set of 
potential gene expression signatures for novel 
targeted therapeutic strategies.
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